6 results about "Baculovirus expression" patented technology

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

The application discloses application of a silkworm silk gland BmSPI45 protein in preparation of a product resisting red hair moss, and relates to the technical field of bioengineering, and has the technical scheme as follows: the application of the silkworm silk gland BmSPI45 protein in preparation of the product resisting red hair moss, and the amino acid sequence of the silkworm silk gland BmSPI45 protein is SEQ ID NO:1.The application uses an insect baculovirus expression system to perform in-vitro expression on a BmSPI45 recombinant protein, and obtains a recombinant pFastBac-BmSPI45 eukaryotic expression vector.The constructed pFastBac-BmSPI45 eukaryotic expression vector is transformed into a DH10Bac competent cell, and a recombinant Bacmid is extracted and obtained, the recombinant Bacmid is transfected, and the BmSPI45 protein is massively expressed.The BmSPI45 recombinant protein is subjected to antibacterial function research, and the result shows that the protein has the effect of resisting red hair moss, thereby providing a new protein alternative for development of an antibacterial preparation.

This invention discloses a fusion multi-epitope antigen of the extracellular region of the rabies virus G protein and its application, belonging to the field of vaccines. This invention uses an insect cell-baculovirus expression system to express a recombinant fusion protein containing the extracellular region of the rabies virus G protein, the dendritic cell targeting peptide DCpep, and the universal T cell epitope PADRE, and displays it on the surface of bacterial-like particles via the peptidoglycan binding domain PA to obtain a recombinant subunit vaccine. Comparative experiments with this vaccine and commercial inactivated vaccines and adjuvanted recombinant subunit vaccines show that the recombinant subunit vaccine provided by this invention has good immunogenicity, can induce specific immune responses in mice and increase neutralizing antibody levels, achieves 100% protection in lethal rabies virus standard strain challenge experiments, significantly reduces viral load in the brain of infected mice, and provides effective challenge protection.

This invention utilizes the recombinant porcine deltacoronavirus protein PDCoV-S constructed in an insect-baculovirus expression system, and uses it as an immunogen to prepare egg yolk antibodies. The egg yolk antibodies are further processed into oral formulations. Through optimization of emulsifiers and synergists, microcapsule formulations with high encapsulation efficiency, high gastric acid throughput, and good intestinal release performance are obtained. Furthermore, the addition of synergists enhances the therapeutic efficacy of the formulation. When the mass ratio of baicalin, Polygonatum odoratum polysaccharide, and nano-selenium is 2:1:2, the encapsulation efficiency of the microcapsules can be effectively improved, thus enhancing the drug's effect. This microcapsule formulation can be used as an active ingredient in the production of drugs or feed additives for the treatment or prevention of PDCoV infection.

The present invention discloses a SmartBac baculovirus expression system and application thereof. The system can comprise a acceptor plasmid (containing fragment A or fragments B and C) and a donor plasmid (containing fragment D); the fragment A contains a promoter, a sequence encoding a protease, a protease cleavage site, an insertion region of a gene encoding a target object to be expressed and a termination sequence; the fragment B contains a promoter, a sequence encoding a protease and a termination sequence; the fragment C contains a promoter, an insertion region of a gene encoding a target object to be expressed and a termination sequence; the fragment D contains a promoter, an insertion region of a gene encoding a target object to be expressed and a termination sequence. The present invention also provides three cloning strategies to achieve the expression of protein complexes with molecular weights of less than 600 kDa and the expression of protein complexes with molecular weights of no less than 600 kDa and efficient screening of a subunit most suitable for adding a purification tag. The present invention is of great significance for recombinantly expressing protein complexes with complex components and large molecular weights in insect cells.

This invention utilizes an insect-baculovirus expression system to prepare the recombinant protein SADS-CoV-S of porcine acute diarrhea syndrome coronavirus, which is then used to prepare egg yolk antibodies. By optimizing the composition of the subunit vaccine composition for immunizing laying hens, IL-2 and ZnCl2 solution are added as immunostimulants to the conventional adjuvant, increasing the antibody concentration in the egg yolk antibody extract and improving the neutralizing antibody titer and protective efficacy. When IL-2 and zinc chloride aqueous solution are added to the immunization composition simultaneously, the resulting egg yolk antibody aqueous solution exhibits the highest protein concentration, and at the same protein concentration, the egg yolk antibody has the highest neutralizing titer. Compared to the immunization composition using Freund's complete adjuvant alone, the neutralizing titer is increased by more than 60 times.